Where is DeepMind’s AI protein design spinout? The Alphabet-owned AI company took the biology world by storm in 2020 with AlphaFold2, the protein structure prediction AI platform that “solved” a decades-old biology problem. In 2021, the company spun out Isomorphic Labs, an AI drug discovery company. But Isomorphic’s initial focus is on small-molecule drug discovery, with protein-based drugs remaining a distant twinkle in the company’s eye.
Watching the Isomorphic spinout was frustrating for Simon Kohl. He was part of the Nobel Prize-winning team that developed Alphafold2, and afterward worked on DeepMind’s protein design team for two years. Isomorphic has a broad vision and is going after many things at once, he told STAT, and he felt a “laser-focused entity” focused on protein design would do a better job.
“I loved working at DeepMind. It’s such a fantastic place and I really enjoyed the time on the AlphaFold team, but really did feel to maximize impact in [protein design], it required its own entity,” said Kohl.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.